Hispanic Men Are More Likely To Suffer From Polyps in Colon Than Women.
Among Hispanics, men are twice as conceivable as women to have colon polyps and are also more disposed to to have multiple polyps, a unusual study in Puerto Rico has found. The researchers also found that the bone up patients older than 60 were 56 percent more likely to have polyps than those younger than 60. Polyps are growths in the gargantuan intestine. Some polyps may already be cancerous or can become cancerous.
The research included 647 patients aged 50 and older undergoing colorectal cancer screening at a gastroenterology clinic in Puerto Rico. In 70 percent of patients with polyps, the growths were on the rational subsidiary of the colon. In white patients, polyps are typically found on the left facet of the colon. This difference may result from underlying molecular differences in the two patient groups, said go into author Dr Marcia Cruz-Correa, an associate professor of medicine and biochemistry at the University of Puerto Rico Cancer Center.
The judgement about polyp location is important because it highlights the straits to use colonoscopy when conducting colorectal cancer screening in Hispanics. This is the most effective approach of detecting polyps on the right side of the colon. The study was to be presented Sunday at the Digestive Diseases Week gathering in New Orleans.
Showing posts with label polyps. Show all posts
Showing posts with label polyps. Show all posts
Friday, 26 February 2016
Sunday, 14 February 2016
New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used
New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used.
A fresh noninvasive assess to locate pre-cancerous polyps and colon tumors appears to be more accurate than tendency noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say. The quest for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a "Holy Grail" of colon cancer research. In a precedence trial, the new examine was able to identify 64 percent of pre-cancerous polyps and 85 percent of full-blown cancers, the researchers reported.
Dr Floriano Marchetti, an aide-de-camp professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the brand-new evaluation could be an important adjunct to colon cancer screening if it proves itself in further study. "Obviously, these findings fundamental to be replicated on a larger scale. Hopefully, this is a good start for a more reliable test".
Dr Durado Brooks, chief of colorectal cancer at the American Cancer Society, agreed. "These findings are interesting. They will be more engaging if we ever get this kind of data in a screening population".
The study's lead researcher remained optimistic. "There are 150000 renewed cases of colon cancer each year in the United States, treated at an estimated fetch of $14 billion," noted Dr David A Ahlquist, professor of pharmaceutical and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn. "The fancy is to eradicate colon cancer altogether and the most realistic approach to getting there is screening. And screening not only in a modus vivendi that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream".
Ahlquist was scheduled to announce the findings of the study Thursday in Philadelphia at a meeting on colorectal cancer sponsored by the American Association for Cancer Research. The recent technology, called the Cologuard sDNA test, mill by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.
If a DNA distortion is found, a colonoscopy would still be needed to confirm the results, just as happens now after a supportive fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist's crew tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.
The assay was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this immensity are considered pre-cancers and most likely to progress to cancer.
A fresh noninvasive assess to locate pre-cancerous polyps and colon tumors appears to be more accurate than tendency noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say. The quest for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a "Holy Grail" of colon cancer research. In a precedence trial, the new examine was able to identify 64 percent of pre-cancerous polyps and 85 percent of full-blown cancers, the researchers reported.
Dr Floriano Marchetti, an aide-de-camp professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the brand-new evaluation could be an important adjunct to colon cancer screening if it proves itself in further study. "Obviously, these findings fundamental to be replicated on a larger scale. Hopefully, this is a good start for a more reliable test".
Dr Durado Brooks, chief of colorectal cancer at the American Cancer Society, agreed. "These findings are interesting. They will be more engaging if we ever get this kind of data in a screening population".
The study's lead researcher remained optimistic. "There are 150000 renewed cases of colon cancer each year in the United States, treated at an estimated fetch of $14 billion," noted Dr David A Ahlquist, professor of pharmaceutical and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn. "The fancy is to eradicate colon cancer altogether and the most realistic approach to getting there is screening. And screening not only in a modus vivendi that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream".
Ahlquist was scheduled to announce the findings of the study Thursday in Philadelphia at a meeting on colorectal cancer sponsored by the American Association for Cancer Research. The recent technology, called the Cologuard sDNA test, mill by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.
If a DNA distortion is found, a colonoscopy would still be needed to confirm the results, just as happens now after a supportive fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist's crew tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.
The assay was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this immensity are considered pre-cancers and most likely to progress to cancer.
Subscribe to:
Posts (Atom)